UPDATE: Oppenheimer Starts Quest Diagnostics (DGX) at Underperform on Restructuring Risk and Bearish Industry Dynamics
Tweet Send to a FriendGet Alerts DGX Hot Sheet
Price: $61.89 -0.8%
Rating Summary:
3 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
3 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade DGX Now!
(Updated - January 29, 2013 8:50 AM EST)
Oppenheimer initiates coverage on Quest Diagnostics (NYSE: DGX) with a Underperform. PT $53.00.
Analyst Bret Jones comments, "While management is taking steps to streamline the company's operations, we believe the industry's headwinds will overshadow progress in the near term. Although a 4.95% reimbursement cut is on the table, if sequestration is averted, we think the industry may have to absorb an even greater pricing decline in a grand bargain scenario. We estimate that, even with the company's proposed cost reductions, reimbursement headwinds will still dominate. With volume growth trailing the industry and cost cutting a multi-year process, we believe the shares of DGX will trail its primary competitor. Therefore, we are initiating coverage with an Underperform rating and a $53 price target."
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $58.24 yesterday, with a 52 week range of $53.25-$64.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Oppenheimer initiates coverage on Quest Diagnostics (NYSE: DGX) with a Underperform. PT $53.00.
Analyst Bret Jones comments, "While management is taking steps to streamline the company's operations, we believe the industry's headwinds will overshadow progress in the near term. Although a 4.95% reimbursement cut is on the table, if sequestration is averted, we think the industry may have to absorb an even greater pricing decline in a grand bargain scenario. We estimate that, even with the company's proposed cost reductions, reimbursement headwinds will still dominate. With volume growth trailing the industry and cost cutting a multi-year process, we believe the shares of DGX will trail its primary competitor. Therefore, we are initiating coverage with an Underperform rating and a $53 price target."
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $58.24 yesterday, with a 52 week range of $53.25-$64.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
- Maxim Group Starts Agenus (AGEN) at Buy, PT $19
- Williams Financial Group Starts Ply Gem Holdings (PGEM) at Buy; Great Way to Play Housing
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
